inspirator schreef op 7 februari 2018 18:52:
Gilead is bezeten van Filgotinib.
Gilead needs Galapagos.
Gilead maakt dit kenbaar in de gepresenteerde jaarcijfers.
We also made great progress in inflammation. Five Phase 3 studies of filgotinib are ongoing in patients with rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Three studies, FINCH 1, 2, and 3, are being conducted in rheumatoid arthritis. The FINCH 2 study is fully enrolled, and we anticipate data from this study in the second half of 2018. FINCH 2 compared filgotinib to placebo, each added to conventional disease-modifying anti-rheumatic drugs, or DMARDs, in patients who have had inadequate response to biologics.
Other studies in rheumatoid arthritis include FINCH 1, a 52-week randomized study comparing filgotinib plus methotrexate to adalimumab plus methotrexate to methotrexate alone in patients who have had inadequate response to methotrexate. And FINCH 3, a 52-week randomized study comparing filgotinib alone to methotrexate alone to the combination of filgotinib plus methotrexate in methotrexate-naïve patients. We anticipate the FINCH 1 and FINCH 3 studies to be fully enrolled later this year.
Filgotinib is also being investigated in five additional Phase 2 studies in other inflammatory diseases, namely, psoriatic arthritis, ankylosing spondylitis, lupus, Sjögren's syndrome, and uveitis, and we should have data available from some of these studies later this year. In addition, just last month we filed an IND on an internally developed small molecule with a novel mechanism of action for inflammatory conditions, and we will initiate clinical development in the coming months.
host.madison.com/business/investment/...